Nijmegen, Netherlands

Floris Louis Van Delft

USPTO Granted Patents = 31 

 

Average Co-Inventor Count = 3.8

ph-index = 6

Forward Citations = 321(Granted Patents)


Location History:

  • KZ Nijmegen, NL (2022)
  • Nijmegen, NL (2014 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
31 patents (USPTO):Explore Patents

Title: Innovations by Floris Louis Van Delft

Introduction

Floris Louis Van Delft, an acclaimed inventor based in Nijmegen, Netherlands, has made significant contributions to the field of biotechnology through his numerous patents. With a total of 28 patents to his name, his work primarily focuses on the development of novel antibody-conjugates and advanced chemical compounds.

Latest Patents

One of his recent patents is for a modified antibody that incorporates a GlcNAc-S(A) substituent. This invention is significant for its application in antibody-conjugates where the N-acetylglucosamine can be optionally fucosylated. Additionally, he has developed fused cyclooctyne compounds, which are pivotal for bioorthogonal labeling and imaging applications, enhancing the capabilities in modifying target molecules.

Career Highlights

Throughout his career, Floris has worked with renowned companies like Synaffix B.V., where he has contributed to innovative projects that have potential implications in therapeutic development. His extensive portfolio showcases not only the inventions but also the methodologies behind creating such complex bioconjugates.

Collaborations

Floris has collaborated with talented professionals in his field such as Maria Antonia Wijdeven and Sander Sebastiaan Van Berkel. These partnerships have been instrumental in pushing the boundaries of research and application in biotechnology, bringing forth impactful inventions that stand out in the scientific community.

Conclusion

Floris Louis Van Delft’s innovative spirit and dedication to advancing biotechnological research are evident through his extensive patent portfolio. His inventions and collaborations are shaping the future of antibody-conjugates and chemical compounds, offering promising avenues in medical applications and beyond.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…